SOLICITATION NOTICE
A -- Multispan Stable Cell Lines (GAL1, GAL2, KOR, DOR, MOR) or Equal
- Notice Date
- 9/10/2018
- Notice Type
- Combined Synopsis/Solicitation
- NAICS
- 541714
— Research and Development in Biotechnology (except Nanobiotechnology)
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute on Mental Health, Contracts Management Branch, 6001 Executive Blvd, Rm 8154, MSC 9661, Bethesda, Maryland, 20892-9661
- ZIP Code
- 20892-9661
- Solicitation Number
- HHSN-NIH-NIDA-RFQ-2018-442
- Archive Date
- 10/2/2018
- Point of Contact
- Bruce E. Anderson, Phone: 3014021655
- E-Mail Address
-
bruce.anderson@nih.gov
(bruce.anderson@nih.gov)
- Small Business Set-Aside
- Total Small Business
- Description
- COMBINED SYNOPSIS / SOLICITATION COMPETITIVE Title: Acquisition of Multispan Stable Cell Lines (GAL 1, GAL 2, KOR, DOR, MOR) or equal 1.This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued. 2.The solicitation number is HHSN-NIH-NIDA-RFQ-2018-506 and the solicitation is issued as a request for quotation (RFQ). 3.The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2005-99, dated June 15, 2018. 4.This acquisition is for a commercial item or service and is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13-Simplified Acquisition Procedures; and FAR Part 12-Acquisition of Commercial Items, and is not expected to exceed the simplified acquisition threshold. 5. This requirement is a total small business set-aside. •The associated NAICS code is 541714, Research and Development in Biotechnology (except Nanotechnology) with a Size Standard of 1000 employees •Certification of business size should be included in the response 6. Description Background Information and Objective: The National Center for Advancing Translational Sciences (NCATS) is a part of the National Institutes of Health (NIH), which mission it is to catalyze the generation of innovative methods and technologies that will enhance the development, testing and implementation of diagnostics and therapeutics across a wide range of human diseases and conditions. As a part of the HEAL (Helping to End Addiction Long-term) Initiative launched by NIH this year, NCATS is currently pursuing screening of several opioid-related targets for primary and follow-up approaches. The GPCR cell lines described here provide a novel and HTS-amenable handle to measure the activity of these important targets. To this end, NCGC is in need of these cell lines to enable these novel drug discovery efforts. 7. Brand Name Items Requested NCATS/NCGC has experience using Multispan cell lines which have been stable and have high expression of receptors on the cell membrane - validated by flow cytometry and functional assays. These cell lines have been used to conduct primary drug screening at NCGC, and will be a useful tool in the secondary characterization of several other NCGC drug targets of interest (meeting several stated needs). Item # Description •CG1178-1 Multispan CHO-K1 Gαqi5 Cell Line Stably Expressing Human GAL1 Receptor, 2 vials (Qty. 1) •C1179-1 Multispan CHO-K1 Cell Line Stably Expressing Human GAL2 Receptor, 2 vials (Qty.1) •C1350-1a Multispan CHO-K1 Cell Line Stably Expressing Human MOR, 2 vials (Qty. 1) •C1352-1a Multispan CHO-K1 Cell Line Stably Expressing Human KOR, 2 vials (Qty. 1) •C1351-1 Multispan CHO-K1 Cell Line Stably Expressing Human DOR, 2 vials (Qty. 1) 8. Generic Name of Product : CHO-K1 Cell Lines Stably Expressing Human GAL 1, GAL 2, KOR, DOR, and MOR 9. Salient Characteristsics Needed for Equivalent a.Cell lines should utilize a common immortalized background line like CHO-K1 or equivalent b.Cell lines should stably express full-length human receptor of interest (GAL1R/GAL2R/KOR/DOR/MOR) c.Lines should utilize a common selection marker, and should remain stable after minimum of two months continuous growth d.Stable cell lines should have high expression of receptors on the cell membrane, validated by flow cytometry and functional assays e.Cell lines should be HTS-amenable and enable primary drug screening at NCGC f.Vendor is responsible for providing the following: •HTS-amenable CHO-K1 lines stably expressing human GAL1R/GAL2R/KOR/DOR/MOR •Cell lines must be scalable to 1536-well format and be compatible with common peristaltic and solenoid valve-based high-throughput dispensers 10. Delivery Location/Date: a.The reagent shall be delivered to NCATS at 9800 Medical Center Drive, Room 1033, Rockville, Maryland 20850 b.One-time delivery within four (4) weeks from award. 11. FAR Clauses/Terms and Conditions •52.211-6 Brand Name or Equal. BRAND NAME OR EQUAL (AUG 1999) (a) If an item in this solicitation is identified as "brand name or equal," the purchase description reflects the characteristics and level of quality that will satisfy the Government's needs. The salient physical, functional, or performance characteristics that "equal" products must meet are specified in the solicitation. (b) To be considered for award, offers of "equal" products, including "equal" products of the brand name manufacturer, must- (1) Meet the salient physical, functional, or performance characteristic specified in this solicitation; (2) Clearly identify the item by- (i) Brand name, if any; and (ii) Make or model number; (3) Include descriptive literature such as illustrations, drawings, or a clear reference to previously furnished descriptive data or information available to the Contracting Officer; and (4) Clearly describe any modifications the offeror plans to make in a product to make it conform to the solicitation requirements. Mark any descriptive material to clearly show the modifications. (c) The Contracting Officer will evaluate "equal" products on the basis of information furnished by the offeror or identified in the offer and reasonably available to the Contracting Officer. The Contracting Officer is not responsible for locating or obtaining any information not identified in the offer. (d) Unless the offeror clearly indicates in its offer that the product being offered is an "equal" product, the offeror shall provide the brand name product referenced in the solicitation. (End of provision) •The provision at FAR clause 52.212-1, Instructions to Offerors - Commercial Items, applies to this acquisition. •The FAR clause at 52.212-4, Contract Terms and Conditions - Commercial Items, applies to this acquisition. •FAR clause at 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders-Commercial Items, applies to this acquisition. •The Defense Priorities and Allocations System (DPAS) are not applicable to this requirement. •The following additional contract requirement(s) or terms and conditions as determined by the contracting officer are necessary for this acquisition and consistent with customary commercial practices: There are no additional contract requirement(s) or terms and conditions applicable to this acquisition. 12.The Government will award a contract resulting from this solicitation to the responsible offeror whose offer conforming to the solicitation will be most advantageous to the Government, price and other factors considered. The following factors shall be used to evaluate offers: Lowest-Priced Technically Acceptable. 13.A written notice of award or acceptance of an offer, mailed or otherwise furnished to the successful offeror within the time for acceptance specified in the offer, shall result in a binding contract without further action by either party. Before the offer's specified expiration time, the Government may accept an offer (or part of an offer), whether or not there are negotiations after its receipt, unless a written notice of withdrawal is received before award. 14. Responses a.Responses to this solicitation must include sufficient information to establish the interested parties' bona-fide capabilities of providing the product or service. The price quote shall include: unit price, list price, shipping and handling costs, delivery days after contract award, delivery terms, prompt payment discount terms, F.O.B. Point (Destination or Origin), product or catalog number(s); product description; and any other information or factors that may be considered in the award decision. Such factors may include: past performance; special features required for effective program performance; trade-in considerations; probable life of the item selected as compared with that of a comparable item; warranty considerations; maintenance availability; and environmental and energy efficiency considerations. b.In addition the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size must be included in the response. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov." c.Include a completed copy of the provision at FAR clause 52.212-3, Offeror Representations and Certifications-Commercial Items, with your offer. d.All responses must be received by Monday, September 17, 2018, by 3PM EST, and reference number HHSN-NIH-NIDA-RFQ-2018-506. Responses may be submitted electronically to Bruce Anderson at bruce.anderson@nih.gov e.Fax responses will not be accepted. f.The name and phone number of the individual to contact for information regarding the solicitation is Bruce Anderson, 301-402-1655
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NIMH/HHSN-NIH-NIDA-RFQ-2018-442/listing.html)
- Place of Performance
- Address: 9800 Medical Center Drive, Bldg. B, Rockville, Maryland, 20850, United States
- Zip Code: 20850
- Zip Code: 20850
- Record
- SN05081185-W 20180912/180910231317-ea7f648119817cef89bdf41e3296877c (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |